|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Rosiglitazone and Cardiovascular Risk
Psaty and Furberg have written a thoughtful and balanced review of the meta–analysis of Avandia safety data published by Dr. Steve Nissen and his co–authors in the same issue of the New England Journal. It is well worth reading in full.
The meta–analysis has a number of strengths. Among these were the effort to include unpublished studies, the prespecified analysis plan, the use of major cardiovascular events as the primary outcome, and an analysis in which rosiglitazone was compared with placebo. In the latter analysis, the odds ratio for myocardial infarction was 1.80 (95% CI, 0.95 to 3.39; P = 0.07), and the odds ratio for death from cardiovascular causes was 1.22 (0.64 to 2.34; P = 0.55).
|home spotlight commentary research events news about contact links archives|